Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH
Clinical trial NCT03920072 · COMPLETED
Trial details
- NCT number
- NCT03920072
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-03-07
- Primary completion
- 2022-04-07
- Enrollment
- 35
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.